FDA Approved Knee Treatment Accused

Genzyme Corp. (Cambridge, MA) has sued Seikagaku Corp. (Tokyo, Japan) and its affiliates and distributors for a declaratory judgment that Seikagaku’s Gel-One product, recently approved by the FDA, will infringe Patent No. 5,399,351 relating to biocompatible viscoelastic gel slurries, in particular for treatment of osteoarthritis in the knee. 

Genzyme Corp. v. Seikagaku Corp., 11-10636-DJC (D. Mass. Apr. 14, 2011)